Novartis to File for Pluvicto Label Expansion After Promising Phase III Data 4/5/2024

Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% of patients do not survive.

New research from the University of Chicago shows the potential for a promising new approach to treating neuroblastoma by targeting RNA modifications associated with the disease.

Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.

The findings, published May 3 in Science, reveal what goes wrong when a group of molecules and enzymes trigger and regulate what's known as the "cell cycle," the repetitive process of making new cells out of the cells' genetic material.

Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the German Center for Infection Research (DZIF) have discovered a new so-called lantibiotic, namely epilancin A37. It is produced by staphylococci that colonize the skin and acts specifically against their main competitors there, the corynebacteria.

Researchers at UNC Lineberger Comprehensive Cancer Center, after decades of research efforts, have developed a mouse model of Kaposi sarcoma that could be key to the development of new drugs to treat the disease. Kaposi sarcoma is a cancer that is the most common cancer in people living with HIV.

The findings appeared in Cell Host & Microbe.

Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B 4/30/2024

Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer 4/30/2024

Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group 4/30/2024

J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program 4/30/2024

AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win 4/30/2024

Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership 4/30/2024

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique 4/30/2024

A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach 4/30/2024

A healthy lifestyle may offset the effects of life-shortening genes by more than 60%, suggests an analysis of the findings from several large long term studies, published online in the journal BMJ Evidence Based Medicine.

While genes and lifestyle seem to have an additive effect on a person's lifespan, an unhealthy lifestyle is independently linked to a 78% heightened risk of dying before one’s time, regardless of genetic predisposition, the research indicates.

Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint 4/29/2024

BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases 4/29/2024

FDA Approves First Targeted Treatment for WHIM Syndrome 4/29/2024

J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate 4/29/2024

Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study 4/29/2024

Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT 4/29/2024